A report detailing a highly unusual request for access to Eli Lilly's experimental obesity drug retatrutide has sparked speculation about whether President Donald Trump could be the mystery patient at the center of the application.
The White House, however, has firmly denied any connection between Trump and the request.
According to a report by STAT, Eli Lilly and the Food and Drug Administration approved a single-patient "compassionate use" application for retatrutide, a next-generation obesity treatment that has produced remarkable weight-loss results approaching those typically achieved through bariatric surgery.
The patient was described as a 79-year-old man suffering from refractory obesity, obstructive sleep apnea, and pulmonary hypertension.
The application reportedly attracted the attention of senior health officials, leading some observers to wonder whether the recipient was a politically connected individual.
STAT noted that the patient's age and health profile led reporters to ask the White House whether the individual was Trump, who recently turned 80 and has publicly discussed obesity medications in the past.
White House spokesman Kush Desai initially referred inquiries to the Department of Health and Human Services and pointed to Trump's recent medical evaluation.
After the story was published, Desai stated on social media that the application "was not for the president."
The speculation comes as Trump's own weight and health have received renewed attention.
A White House medical report released this year listed the president at 238 pounds and 6 feet, 3 inches tall, placing him near the threshold for clinical obesity.
The report also showed that Trump had gained 14 pounds since his April 2025 examination, when he weighed 224 pounds.
Despite the increase, White House physician Sean Barbabella concluded that Trump remains in "excellent health" and is fully capable of carrying out the duties of the presidency.
The report recommended continued weight loss, increased physical activity, and dietary improvements.
Trump has previously expressed interest in the rapidly growing class of GLP-1 weight-loss drugs.
During policy discussions on prescription drug costs, he highlighted the popularity and effectiveness of medications such as Wegovy, Ozempic, and Lilly's tirzepatide.
His administration has also promoted efforts aimed at lowering the cost of obesity treatments, reflecting an acknowledgment of the drugs' growing role in American healthcare.
Retatrutide is viewed by many obesity specialists as one of the most promising experimental weight-loss drugs currently in development.
Lilly reported that patients with obesity who remained on the drug for 80 weeks lost an average of 28% of their body weight, a figure approaching outcomes commonly seen with bariatric surgery.
The drug targets three separate metabolic pathways and is expected to seek FDA approval later this year.
For now, there is no evidence linking Trump to the compassionate-use application.
Nevertheless, the combination of the president's recent weight gain, his public comments about obesity medications, and the unusual circumstances surrounding the request has fueled continued public interest.
The White House's denial appears intended to put those questions to rest, even as attention remains focused on the next generation of powerful weight-loss treatments.